ARTICLE | Clinical News
Peg-Intron fails Phase III CML study
June 11, 2001 7:00 AM UTC
In a Phase III study of Peg-Intron peginterferon alfa-2b from Enzon (ENZN) and partner Schering-Plough (SGP) in patients with chronic myelogenous leukemia (CML), the once weekly product failed to meet...